@medoncodoc

Asst Prof, Medical Oncology @GCRI_1972 @offcmcvellore alumni #pantumor 🧬🌐, Academic account, #medtwitter. Follow @gsrocks007 for personal account.

 India
medoncodoc.com
Joined December 2009
  • Tweets3.8K
  • Following486
  • Followers1.1K
416Media
Sequencing EGFR mabs in 1L RAS WT, left-sided #mCRC - CR-SEQUENCE trial @RamonSalazarS Practical Summary by @BiachiTiago & Dr Richard Kim @MoffittNews PFS rates not significantly different! Would you change practice? #oncology #cancer #medtwitter
4
14
1,400
Goutham Sunny retweeted
Brendan Guercio
@BrendanGuercioJun 28
Was a pleasure to discuss practice-changing updates in prostate cancer from #ASCO2026 with @TiansterZhang. Through addition of perioperative ADT+ARPI, PROTEUS offers a new radiation-free approach for high-risk prostate cancer. In TALAPRO-3, the addition of the PARP inhibitor talazoparib to enzalutamide improved rPFS in HRR-altered metastatic castration-sensitive prostate cancer, both in BRCA-mutated (HR 0.37) and non-BRCA mutated (HR 0.57) patients! OS also trended in the right direction (HR 0.77), looking forward to mature OS data soon. @OncUpdates @OncBrothers @WilmotCancer @urmed_urology @URMed_DeptMed
OncUpdates
@OncUpdatesJun 26
⭐️Practice-Changing Updates in #ProstateCancer #ASCO26 🤩@BrendanGuercio & @TiansterZhang 🗣️ ✅PROTEUS: Perioperative apalutamide+ ADT→Improved pCR/MRD+MFS ✅TALAPRO-3: Talazoparib+enzalutamide benefits HRR-deficient mCSPC #OncTwitter #GUsm #pcsm #MedX oncupdates.com/video-podcast…

Practice-Changing Updates for Prostate Cancer From ASCO 2026 - OncUpdates

Medical oncologists, Brendan Guercio, MD, of Wilmot Cancer Institute, and Tian Zhang, MD, MHS, of UT Southwestern, discuss the potentially practice-changing data from the PROTEUS and TALAPRO-3...

oncupdates.com
3
10
2,015
Goutham Sunny retweeted
David Young M.D.@davideyoungmdJun 8
Replying to @adamfeuerstein
Vopimetostat is a PRMT5 inhibitor. Activating mutations of PRMT5 are found in up to 45% of pancreatic cancer and is involved in the growth of the tumor. Hitting KRAS with one drug and PRMT5 with another drug makes sense, as long as side effects are not trebled.
1
1
7
580
$TNGX vopimetostat + daraxonrasib ORR PDAC
3
17
7
55
99,076
Sharing a great initiative by my colleague @DrRishabhOnco to navigate the ever-growing maze of oncology clinical trials (And my contribution to it as well) Had a lot of fun curating the "noise" section! Check out oncosignals-asco-2026.netlif… @ASCO #asco26 #asco #cancer
1
2
5
439
Goutham Sunny retweeted
Dr Akhil Kapoor@drakhilkapoor1May 24
Two ASCO Education Book 2026 publications from Tata Memorial Centre highlight pragmatic oncology innovations for LMICs — including low-dose immunotherapy, toxicity management, affordability, and metronomic approaches in cancer care. Honoured to contribute as co-author. #ASCO
7
14
1
55
1,747
🤩 Finally OUT in @JCO_ASCO! BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy A decade of persistence from @VedangMurthy ☺️ @RadOncTMC @TataMemorial @ACTREC_TMC @PaulSargos @Xristodouleas ascopubs.org/doi/full/10.120…

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant...

PURPOSETo report the primary analysis of a multicenter, phase III randomized trial of adjuvant radiotherapy (RT) after chemotherapy and radical cystectomy (RC) in patients with high-risk muscle-inv...

ascopubs.org
13
63
2
140
9,463
Goutham Sunny retweeted
Dr Sarah Sammons
@drsarahsamMay 23
FDA approves Dato-DXd (Datroway) for 1L metastatic TNBC in patients ineligible for immunotherapy (70% of pts). Now we have 2 TROP2 ADCs in same indication; we can only use 1 upfront. TROPION-Breast02 vs ASCENT-03: similar PFS (10.8 vs 9.7 mo), OS (23.7 vs 21.5 mo), and DOR (12.3 vs 12.2 mo). Dato-DXd showed higher ORR (62.5% vs 48%), a very different side effect profile (stomatitis/dry eye vs neutropenia/diarrhea), Q3W vs days 1+8 dosing. Nice brain metastases activity with Dato-DXd; HR of 0.3 in the brain mets subgroup. DFI pts <6 months only included in Dato-DXd trial. For IO-ineligible mTNBC, we have two nice options. #TNBC #breastcancer #oncology
2
27
4
74
11,887
Goutham Sunny retweeted
Papa Heme
@Papa_HemeMay 23
Please urge everyone to sit down spend an hour reading the AQUILA trial before blindly listening to experts and prescribing daratumumab for smoldering myeloma.
5
7
1
76
9,958
Goutham Sunny retweeted
Oncology Brothers
@OncBrothersMay 22
DatoDXd now @US_FDA ✅ in 1L mTNBC in PDL1 negative/IO ineligible based off TROPION-Breast02 - mPFS 10.8 vs 5.6mos (HR: 0.57) - mOS 23.7 vs. 18.7mos (HR: 0.79) - ORR 62.5% vs. 29.3% - Common AEs: mucositis & occular AEs #OncTwitter #bcsm @OncUpdates
5
41
3
71
11,755
1/ASCO 2026 is days away and your feed is filling with "abstracts/presentation I'm most excited about." My pick is ...probably on nobody's list. The whole story is about one dose. Give me 90 seconds. It may worth a read.
6
49
5
126
24,915
This is far more than just another #FDA update; it’s a total rewrite of the first-line standards for Triple-Negative Breast Cancer (TNBC)! For metastatic TNBC patients who aren't eligible for immunotherapy, we have historically relied on standard chemotherapy. The approval of the TROP2-directed ADC Datopotamab Deruxtecan (Dato-DXd) shatters that ceiling. #BreastCancer #TNBC #Oncology #MedTwitter #FDAApproval
🤖 Made with AI
3
16
1
29
1,446
Head & Neck Cancer #ASCO2026 oral abstracts in a nutshell: No breakthroughs—but pragmatic progress with emerging signals of what’s next.
12
2
38
4,940
Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/pdf/10.1200… @JCOOP_ASCO @ASCO @OncoAlert one of the most common consults in General HemOnc Clinics
2
48
1
130
12,202
Goutham Sunny retweeted
WabiSabi
@Geeky_FoodieMay 19
So now even taxanes supply is under threat. If the authorities can’t ensure that stocks of non expensive essential life saving cancer drugs are restored, request them to atleast issue an official legal order that absolves medical oncologists from the legal liability of inferior treatments and outcomes thanks to national shortage of these drugs, coz while we would very much like saving lives, when that is not facilitated by the Government and the global situation, we would very much like to atleast save our @$$! @MoHFW_INDIA @PMOIndia @JPNadda
WabiSabi
@Geeky_FoodieMay 18
In oncology we say one size doesn’t fit all, but if there are any drugs that work in almost all cancers, they have to be platinum drugs especially Cisplatin and Carboplatin. The simplest, effective and cheapest drugs that have no replacement in several cancers are out of stock in most hospitals in India, leaving patients and families to suffer with no treatments even in curable cancers. The global supply chain has been massively impacted, so are the import rates and manufacturing rates. While capping prices of drugs is a welcome move, flexibility that is reviewed dynamically is the need of the hour, a 50% rise in capped price of a 200 rupees drug that is life saving should be accommodated as the cost of lives lost is going to be much more. Request @narendramodi @PMOIndia @JPNadda @MoHFW_INDIA @AmitShahOffice to resolve the situation ASAP
3
10
23
2,393
Goutham Sunny retweeted
WabiSabi
@Geeky_FoodieMay 18
In oncology we say one size doesn’t fit all, but if there are any drugs that work in almost all cancers, they have to be platinum drugs especially Cisplatin and Carboplatin. The simplest, effective and cheapest drugs that have no replacement in several cancers are out of stock in most hospitals in India, leaving patients and families to suffer with no treatments even in curable cancers. The global supply chain has been massively impacted, so are the import rates and manufacturing rates. While capping prices of drugs is a welcome move, flexibility that is reviewed dynamically is the need of the hour, a 50% rise in capped price of a 200 rupees drug that is life saving should be accommodated as the cost of lives lost is going to be much more. Request @narendramodi @PMOIndia @JPNadda @MoHFW_INDIA @AmitShahOffice to resolve the situation ASAP
8
33
7
82
9,526
Goutham Sunny retweeted
bhawna sirohi@SirohiBhawnaMay 14
This is a global issue for both Cisplatin and carboplatin .. @ChandrakanthMv needs to be highlighted … affecting so many pts @AyushmanNHA @CancerGridIndia @cspramesh @ASCO @DrSanjayPopat @myESMO … not an expensive drug so industry not bothered. @PMOIndia @JPNadda @ICMRDELHI @jrgralow @drkiwicj
MV Chandrakanth
@ChandrakanthMvMay 14
• Platinum chemotherapy shortage in India is becoming a major oncology challenge • Cisplatin & carboplatin are backbone drugs across many cancers • The issue is not just “drug availability” → raw material crisis → pricing pressure → manufacturing economics → supply-chain disruption • Real-world impact: → treatment delays → dose modifications → regimen changes → inventory pressure • Quick visual summary of: ✓ What is happening ✓ Why it is happening ✓ Clinical implications ✓ Possible solutions Would like to hear how different centres are managing this situation. #Oncology #CancerCare #DrugShortage #Cisplatin #Carboplatin #Chemotherapy #OncTwitter #MedTwitter #MVOnco
1
2
8
473
Reviewing 1L options in advanced #HCC Atezo Bev still has the strongest signal and longest followup - across multiple subsets. ✅ AFP>400 ✅ Vp4 portal invasion ✅ Viral HCC ❓MAFLD ❓ Fibrolamellar TKIs with signals - Sora, Lenva, Cabo, Regora @OncoDailyGI @oncodaily #cancer
2
23
54
2,840
Goutham Sunny retweeted
Yakup Ergün
@dr_yakupergunApr 18
One of the most notable studies from #AACR26: Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC. ORR 58% DCR 90% 6-month PFS 84%!! Things are finally moving in pancreatic cancer👇 aacrjournals.org/cancerres/a…
3
40
3
128
12,537
Goutham Sunny retweeted
Pramesh CS
@csprameshApr 19
Never forget this. Time is finite... Family always comes first. Courtesy @jenna_taglienti
1
44
4
145
7,922
Load more